AegirBio AB (publ)

As of June 30, 2025, AegirBio AB (publ) has 1.86M shares outstanding.

These figures are as of June 30, 2025. The EV/Sales ratio of 0.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. AegirBio AB (publ) trades at an EV/FCF ratio of 0.08, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, AegirBio AB (publ) maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -72.04, indicating conservative leverage, while an interest coverage ratio of -0.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, AegirBio AB (publ) posted a negative return on equity (ROE) of -24.12, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -56.89, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -187.15, pointing to unprofitable operations over the period.

These figures cover the twelve months ended June 30, 2025. That works out to an effective tax rate of 12.46, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on August 5, 2024, AegirBio AB (publ)'s stock has declined approximately 70.88% over the past 52 weeks. The 50-day moving average sits at 0.48, while the 200-day moving average is 0.72.

Over the twelve months ended June 30, 2025, AegirBio AB (publ) posted a gross margin of 69.44, reflecting its pricing power and cost economics. The operating margin of -0.92 and net profit margin of -11.97 provide insight into operational efficiency.

AegirBio AB (publ)'s most recent stock split took place on June 8, 2022 with a 1000:1089 split ratio.

As of June 30, 2025, AegirBio AB (publ) has an Altman Z-Score of -197.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.